4.8 Article

Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy

Journal

CELL
Volume 175, Issue 3, Pages 766-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2018.09.027

Keywords

-

Funding

  1. NCI NIH HHS [P30 CA060553, R01 CA214035, T32 CA070085, R50 CA211428] Funding Source: Medline
  2. NINDS NIH HHS [R01 NS093079] Funding Source: Medline
  3. NATIONAL CANCER INSTITUTE [P30CA060553, T32CA070085, R50CA211428, R01CA214035] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS093079] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The super elongation complex (SEC) is required for robust and productive transcription through release of RNA polymerase II (Pol II) with its P-TEFb module and promoting transcriptional processivity with its ELL2 subunit. Malfunction of SEC contributes to multiple human diseases including cancer. Here, we identify peptidomimetic lead compounds, KL-1 and its structural homolog KL-2, which disrupt the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC is required for induction of heat-shock genes and treating cells with KL-1 and KL-2 attenuates the heat-shock response from Drosophila to human. SEC inhibition downregulates MYC and MYC-dependent transcriptional programs in mammalian cells and delays tumor progression in a mouse xenograft model of MYC-driven cancer, indicating that small-molecule disruptors of SEC could be used for targeted therapy of MYC-induced cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available